Drug Profile
Tumour necrosis factor alpha kinoid
Alternative Names: TNF-K; TNF-K005; TNFα-kinoidLatest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator Neovacs
- Class Antirheumatics; Antiulcers; Vaccines
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Rheumatoid arthritis
Most Recent Events
- 07 Sep 2021 Discontinued - Phase-I/II for Crohn's disease in South Africa, Switzerland (IM) (Neovacs pipeline, September 2021)
- 07 Sep 2021 Discontinued - Phase-II for Crohn's disease in France, Belgium, Germany, Netherlands, Bulgaria, Czech Republic, Hungary, Croatia, Romania (IM) (Neovacs pipeline, September 2021)
- 07 Sep 2021 Discontinued - Phase-II for Rheumatoid arthritis in Argentina, Belgium, Bulgaria, Chile, Croatia, Czech Republic, France, Georgia, Hungary, Lebanon, Macedonia, Moldova, Poland, Romania, Russia, Serbia, Ukraine (IM) (Neovacs pipeline, September 2021)